Roberta Tarallo
Overview
Explore the profile of Roberta Tarallo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexandrova E, Smal M, Di Rosa D, Brancaccio R, Parisi R, Russo F, et al.
Sci Rep
. 2025 Mar;
15(1):7602.
PMID: 40038391
Ovarian Cancer (OC) is the most lethal gynecological malignancy, characterized by peritoneal metastasis, directly linked to most OC-related deaths. Here, by interrogating CRISPR-Cas9 loss-of-function genetic screen data, we identified a...
2.
Melone V, Palumbo D, Palo L, Brusco N, Salvati A, Tarallo A, et al.
Cell Death Dis
. 2025 Feb;
16(1):80.
PMID: 39922814
RNA-based therapeutics highlighted novel approaches to target either coding or noncoding molecules for multiple diseases treatment. In breast cancer (BC), a multitude of deregulated long noncoding RNAs (lncRNAs) have been...
3.
Salvati A, Giurato G, Lamberti J, Terenzi I, Crescenzo L, Melone V, et al.
Mol Cancer
. 2024 Aug;
23(1):160.
PMID: 39113071
Identifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In breast cancer (BC), resistance...
4.
Smal M, Memoli D, Alexandrova E, Di Rosa D, DAgostino Y, Russo F, et al.
Sci Data
. 2024 Jul;
11(1):767.
PMID: 38997254
Small non-coding RNAs (sncRNAs) make up ~1% of the transcriptome; nevertheless, they play significant roles in regulating cellular processes. Given the complexity of the central nervous system, sncRNAs likely hold...
5.
Giurato G, Terenzi I, Chiuso F, Salvati A, Rizzo F, Tarallo R, et al.
Front Cell Dev Biol
. 2023 Dec;
11:1308025.
PMID: 38099289
No abstract available.
6.
Author Correction: Host nasopharyngeal transcriptome dataset of a SARS-CoV-2 positive Italian cohort
Salvati A, Ferravante C, Lamberti J, Rocco T, Alexandrova E, DAgostino Y, et al.
Sci Data
. 2023 Sep;
10(1):588.
PMID: 37679338
No abstract available.
7.
Salvati A, Ferravante C, Lamberti J, Rocco T, Alexandrova E, DAgostino Y, et al.
Sci Data
. 2023 Jun;
10(1):379.
PMID: 37316506
The ongoing COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people worldwide and has significant implications for public health. Host transcriptomics profiling provides comprehensive understanding of how the virus...
8.
Melone V, Salvati A, Brusco N, Alexandrova E, DAgostino Y, Palumbo D, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36674656
In the complex and articulated machinery of the human genome, less than 2% of the transcriptome encodes for proteins, while at least 75% is actively transcribed into non-coding RNAs (ncRNAs)....
9.
Vieceli Dalla Sega F, Palumbo D, Fortini F, DAgostino Y, Cimaglia P, Marracino L, et al.
Sci Rep
. 2022 Nov;
12(1):20400.
PMID: 36437309
Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of clones of mutated blood cells without overt blood diseases. In the last few years, it has emerged that...
10.
Alexandrova E, Lamberti J, Memoli D, Quercia C, Melone V, Rizzo F, et al.
Cancer Cell Int
. 2022 Nov;
22(1):336.
PMID: 36333801
Background: Ovarian cancer (OC) is characterized by a low response rate and high frequency of resistance development to currently available treatments. The therapeutic potential of histone methyltransferase DOT1L inhibitor in...